Related references
Note: Only part of the references are listed.The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?
Peer Tfelt-Hansen et al.
HEADACHE (2019)
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski et al.
CEPHALALGIA (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine A Randomized Clinical Trial
David W. Dodick et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Targeted 5-HT1F Therapies for Migraine
Marta Vila-Pueyo
NEUROTHERAPEUTICS (2018)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Virginia L. Stauffer et al.
JAMA NEUROLOGY (2018)
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
Todd Schwedt et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Bernice Kuca et al.
NEUROLOGY (2018)
Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice
Jessica C. Oswald et al.
JOURNAL OF PAIN RESEARCH (2018)
Phase I, Randomized, Double-blind, Placebo-controlled, Single-dose, and Multiple-dose Studies of Erenumab in Healthy Subjects and Patients With Migraine
Jan de Hoon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines
Joshua M. Cohen et al.
HEADACHE (2017)
Human models of migraine - short-term pain for long-term gain
Messoud Ashina et al.
NATURE REVIEWS NEUROLOGY (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PATHOPHYSIOLOGY OF MIGRAINE: A DISORDER OF SENSORY PROCESSING
Peter J. Goadsby et al.
PHYSIOLOGICAL REVIEWS (2017)
Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab
Maria Adele Giamberardino et al.
JOURNAL OF PAIN RESEARCH (2017)
Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine
Tony W. Ho et al.
CEPHALALGIA (2016)
A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine
Tiffini Voss et al.
CEPHALALGIA (2016)
TEV-48125 for the preventive treatment of chronic migraine: Efficacy at early time points
Marcelo E. Bigal et al.
NEUROLOGY (2016)
Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor
Licheng Shi et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program
Marcelo E. Bigal et al.
CEPHALALGIA (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan
Paul B. Rizzoli
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2014)
Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews
Christopher J. Derry et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR Review 1
Anthony J. Harmar et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Publication committees in clinical trials in headache
Peer Carsten Tfelt-Hansen et al.
CEPHALALGIA (2012)
Discovery of (5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): An Oral Calcitonin Gene-Related Peptide (CGRP) Antagonist in Clinical Trials for Treating Migraine
Guanglin Luo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Preclinical pharmacological profile of the selective 5-HTIF receptor agonist lasmiditan
David L. Nelson et al.
CEPHALALGIA (2010)
What have we learnt from triggering migraine?
Henrik W. Schytz et al.
CURRENT OPINION IN NEUROLOGY (2010)
PACAP38 induces migraine-like attacks in patients with migraine without aura
Henrik Winther Schytz et al.
BRAIN (2009)
The vascular theory of migrainea great story wrecked by the facts
Peter J. Goadsby
BRAIN (2009)
Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine
A. Rahmann et al.
CEPHALALGIA (2008)
BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation
KA Petersen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers
KA Petersen et al.
CEPHALALGIA (2005)
Calcitonin gene-related peptide receptor antagonist BIBN4096BS for the acute treatment of migraine
J Olesen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vascular actions of calcitonin gene-related peptide and adrenomedullin
SD Brain et al.
PHYSIOLOGICAL REVIEWS (2004)
Drug therapy: Migraine - Current understanding and treatment.
PJ Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2
R Uddman et al.
CEPHALALGIA (2002)
Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine:: a randomised controlled trial
DJ Goldstein et al.
LANCET (2001)
Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine
B Gomez-Mancilla et al.
CEPHALALGIA (2001)
5-HT1B and 5-HT1D receptors in the human trigeminal ganglion:: co-localization with calcitonin gene-related peptide, substance P and nitric oxide synthase
MY Hou et al.
BRAIN RESEARCH (2001)
Co-localization of 5-HT1B/1B/1F receptors and glutamate in trigeminal ganglia in rats
QP Ma
NEUROREPORT (2001)
Share Paper
